Scores are 0 to 100 against every US stock we track; 50 is average. Recomputed after every US market close.
Fiscal year to December 2025, from the company's annual filing with the SEC.
| Salesyearly sales | $4.7B |
| Sales growthchange from the year before | +15.6% |
| Gross marginshare of sales left after the direct cost of what it sells | 60.1% |
| Operating marginshare of sales left after running the business | 19.6% |
| Net marginshare of sales kept as profit | 17.9% |
| Free-cash-flow marginspare cash generated per $100 of sales | 23.1% |
| Return on invested capitalprofit made on each $100 put into the business | 26.2% |
| Return on equityprofit vs. shareholders' accounting value | 30.5% |
| Interest coverhow many times profit covers interest payments | 63.8x |
| Change in share countnegative = the company is buying back its shares | -1.7% |
2 insiders sold $2.4M (all under pre-arranged plans) on the open market.
| Foletta Mark GDirector | Sold (plan)Aug 3 | 2,000 shat $85.32 · $171K |
| Foletta Mark GDirector | Sold (plan)Jul 31 | 2,000 shat $80.00 · $160K |
| Sayer Kevin RExecutive Chair · Director | Sold (plan)Jul 20 | 26,756 shat $76.32 · $2.0M |
From Form 4 filings with the SEC. Open-market trades only. "Plan" = a sale set up in advance under a 10b5-1 plan, usually routine.
Not financial advice. Research and education only: the same view for everyone, with no regard to your circumstances. Past results do not predict future ones. Decide for yourself or with a licensed adviser. Terms · Privacy